ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SAVA Cassava Sciences Inc

22.05
0.00 (0.00%)
Pre Market
Last Updated: 12:18:11
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cassava Sciences Inc NASDAQ:SAVA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 22.05 22.10 22.30 428 12:18:11

Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ET

11/09/2020 9:01pm

GlobeNewswire Inc.


Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cassava Sciences Charts.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Monday, September 14th at 8:30 a.m. Eastern Time. 

Event details follow:
Date:Monday, September 14th
Time:8:30 a.m. Eastern Time
Audio Webcast:https://www.CassavaSciences.com/company-presentations
Dial-In:1-800-920-4315
Conference ID:21969265

The dial-in number for international callers is 1-212-231-2929. A replay of the webcast will remain available in the ‘Investors’ section of Cassava Sciences’ website, www.CassavaSciences.com, for 90 days following the conference. In addition, a telephonic replay of the call will be available until September 28, 2020. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use the replay conference ID number 21969265.

About Cassava Sciences, Inc.Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third-party.

For More Information Contact:Eric Schoen, Chief Financial OfficerCassava Sciences, Inc.eschoen@CassavaSciences.com(512) 501-2450

1 Year Cassava Sciences Chart

1 Year Cassava Sciences Chart

1 Month Cassava Sciences Chart

1 Month Cassava Sciences Chart

Your Recent History

Delayed Upgrade Clock